Optimal Dose https://validator.w3.org/feed/docs/rss2.html GlycoNex Inc. and Nippon Kayaku Co., Ltd. enter collaboration to advance next-generation ADC candidate GNX201-ADC ENHERTU approved in Japan as first tumor agnostic HER2 directed medicine for previously treated patients with HER2 positive metastatic solid tumors ENHERTU now available in Japan as first ADC for the second-line treatment of patients with HER2 positive metastatic gastric cancer Chugai obtains regulatory approval for Lunsumio and Polivy combination therapy for additional indication of relapsed or refractory large b-cell lymphoma GSK’s B7-H3-targeted ADC, Risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in Japan Optimal Dose – CAR-T Digest (August 2020) Trastuzumab Ruikang has received BTD from China’s NMPA for the treatment of HER2‑positive breast cancer Weekly News 18 April to 24 April 2026 Weekly News 18 April to 24 April 2026 SHR‑A2102 has received BTD from China’s NMPA for the treatment of cervical cancer U.S. FDA grants Priority Review to sBLA for PADCEV + Keytruda as perioperative treatment for MIBC regardless of Cisplatin eligibility Mabwell initiates phase 3 clinical study of its Nectin-4 targeting ADC 9MW2821 for the treatment of TNBC Blenrep approved in China for treatment of 2L+ relapsed/refractory multiple myeloma Servier completes the acquisition of Day One Biopharmaceuticals 3B Pharmaceuticals and TetraKit Technologies announce strategic collaboration for joint radioligand therapy (RLT) development Ifinatamab Deruxtecan receives U.S. Priority Review for previously treated extensive-stage SCLC progressing after platinum-based chemotherapy Weekly News 11 April to 17 April 2026 Weekly News 11 April to 17 April 2026 CSPC Pharmaceutical Group Limited obtains NMPA clinical trial approval for TF-targeted ADC SYS6051 in China CrossBridge Bio enters an agreement to be acquired by Eli Lilly to advance next-generation dual-payload ADCs GlycoNex receives PMDA approval in Japan to initiate first-in-human phase 1 trial of GNX1021 in gastrointestinal cancers Disitamab Vedotin approved in china as first line therapy for HER2 expressing urothelial carcinoma Weekly News 04 April to 10 April 2026 Weekly News 04 April to 10 April 2026 Corbus Pharmaceuticals announces broad alignment with FDA on registration path for CRB-701 in second-line HNSCC and cervical cancer Akari Therapeutics announces strategic partnership with WuXi XDC to advance development of its novel ADC payload targeting RNA splicing The New Drug Application (NDA) for DB-1303/BNT323 for unresectable or metastatic HER2-positive adult breast cancer has been accepted by the NMPA Sidewinder Therapeutics announces $137 million series B financing to advance precision bispecific ADCs into clinical development for cancer Celltrion ADC drug candidate CT-P71 receives FDA Fast Track Designation for urothelial carcinoma NextCure receives Fast Track Designation for SIM0505 (CDH6 ADC) in ovarian cancer Zai Lab announces global clinical trial collaboration and supply agreement to evaluate novel DLL3 ADC, Zocilurtatug Pelitecan, in combination with a bispecific T-cell Engager therapy RemeGen’s dual-antibody ADC RC288 for the treatment of advanced malignant solid tumors has been officially approved for clinical trials Weekly News 28 March to 03 April 2026 Zymeworks receives U.S. FDA Fast Track Designation for ZW191, an FRα-targeting ADC Weekly News 28 March to 03 April 2026 ENHERTU followed by THP approved in China as the first and only HER2 directed ADC for the neoadjuvant treatment of HER2 positive breast cancer Aktis Oncology announces FDA clearance of Investigational New Drug applications for AKY-2519 NJ Bio and Ajinomoto Bio-Pharma Services partner to advance ADC and AOC development Monthly Digest – April 2026 Monthly Digest – April 2026 Tacalyx secures €11 million to advance lead TACA-targeting ADC programme toward the clinic SYS6051 obtains clinical trial approval in the U.S. Weekly News 25 April to 01 May 2026 Weekly News 25 April to 01 May 2026 Novartis withdraws EMA application for adding new indication for Pluvicto Taiho Pharmaceutical and Araris Biotech AG advance ADC ARC-02 into phase 1 clinical development Alphamab Oncology announces IND application for TROP2/HER3 bispecific ADC JSKN016SC officially accepted by CDE The NMPA has granted BTD for B7-H3-targeted ADC HS-20093 for castration-resistant prostate cancer Monthly Digest – May 2026 Monthly Digest – May 2026